Potent growth hormone releasing peptide (GHS-R agonist)
Examorelin
A very potent GH secretagogue studied for cardioprotective and GH effects; not FDA approved therapeutically.
- Evidence:
- Limited human evidence
- Status:
- Not FDA-approved
- Reviewed:
- 2026-08-03
Also known as: Examorelin, HEX
What is Examorelin?
A very potent GH secretagogue studied for cardioprotective and GH effects; not FDA approved therapeutically.
This profile is educational. It organizes publicly discussed research context for Examorelin and related naming aliases — it is not a treatment guide.
Proposed mechanism
Strong GHS-R agonism producing sharp GH pulses; also studied for direct cardiac CD36 receptor effects independent of GH.
Mechanism language on PepGuide describes how researchers discuss pathways. Proposed mechanisms can change as evidence evolves.
Current research notes
Human evidence grade: Limited human evidence
Preclinical evidence grade: Moderate human evidence
Hexarelin produces among the largest GH responses of GHRPs. Studied for cardiac protection in animal models. Desensitization with continuous use observed. WADA prohibited. Human GH data exist; therapeutic development limited.
Key uncertainties
- Cardioprotective translation to humans
Research areas being studied
- GH axis
- Cardioprotection research
- Cachexia
Being studied for a topic is not the same as proven benefit in that topic. Prefer primary literature for study design, endpoints, and limitations.
Safety & side-effect notes
Reported or discussed adverse effects
- Cortisol increase
- Prolactin increase
- Water retention
Additional risks & considerations
- Tachyphylaxis with chronic use
- Cortisol/prolactin elevation
- WADA prohibited
Regulatory status
Not FDA-approved
Regulatory framing here is educational and can lag policy changes. Check official sources for current status.
Frequently asked questions
What is Examorelin?
A very potent GH secretagogue studied for cardioprotective and GH effects; not FDA approved therapeutically.
How does Examorelin work (proposed mechanism)?
Strong GHS-R agonism producing sharp GH pulses; also studied for direct cardiac CD36 receptor effects independent of GH.
What is Examorelin being researched for?
Examorelin has been discussed in research contexts including: GH axis, Cardioprotection research, Cachexia.
What does current evidence say about Examorelin?
Limited human evidence. Hexarelin produces among the largest GH responses of GHRPs. Studied for cardiac protection in animal models. Desensitization with continuous use observed. WADA prohibited. Human GH data exist; therapeutic development limited.
What safety considerations are noted for Examorelin?
Reported or discussed considerations include: Cortisol increase; Prolactin increase; Water retention; Tachyphylaxis with chronic use; Cortisol/prolactin elevation; WADA prohibited. This is educational information, not medical advice.
References & sources
- Camanni F et al. (1998). Hexarelin pharmacodynamics in humans — J Clin Endocrinol Metab. Evidence type: human.
Prefer interactive tools? Open the PepGuide library entry for Examorelin or ask PepGuide AI.
Educational and research information only. PepGuide does not sell or prescribe peptides, diagnose conditions, or provide personalized medical advice. Evidence summaries may include early-stage, animal, or limited human research — none of that is a substitute for primary literature or clinician guidance.